ECB’s de Guindos says does not think the central bank’s Q4 growth projections will be met 0 (0)

Comments by ECB vice president, Luis de Guindos
He’s highlighting the double-dip recession risk as the tighter restrictions implemented at the start of the month looks set to continue into December as well, considering that the virus situation in many countries have yet to abate.

Go to Forexlive

Brexit: Gaps said to be only slowly shrinking on three core issues, growing concern of time left 0 (0)

BBC Europe editor, Katya Adler, tweets
After a briefing to member states on state of play in EU-U.K. negotiations, EU diplomat says: „Gaps are only slowly shrinking on core issues like level playing field, governance and fisheries.“ Says there’s growing concern enough time left.
Essentially, both sides are still waiting on the other to budge on the

Go to Forexlive

UK November CBI trends total orders -40 vs -40 expected 0 (0)

Latest data released by UK CBI – 19 November 2020
UK manufacturing orders is seen declining at a quicker pace in November, with order books seen softening again amid more lockdowns across the region. Of note, output volumes have declined to their slowest pace in over a year, according to CBI.

Go to Forexlive

Brexit: Barnier reportedly cancels briefings to EU side planned for next week 0 (0)

BBC political editor, Laura Kuenssberg, reports
„Barnier has cancelled briefings to EU side – planned for Tues night and then Weds lunchtime – only a hint, but perhaps a good sign that negotiators are churning through the obstacles to a deal, working not briefing!“

Go to Forexlive

Another round of vaccine optimism rinse and repeat 0 (0)

But to a lesser degree and perhaps shorter lasting timeframe
Pfizer passed the final hurdle of meeting the safety requirements to apply for emergency-use approval, but the announcement also came with a bit of an attempt to try and one up Moderna as they claim that their vaccine is 95% effective upon final analysis.

Go to Forexlive

Pfizer says have achieved safety data milestone required by FDA, vaccine efficacy 95% in final analysis 0 (0)

Pfizer plans to file for emergency-use authorisation from the FDA
– Vaccine shown to be 95% effective in final efficacy analysis of Phase 3 trial
– Plans to file for emergency-use authorisation within days
Risk trades are getting another shot in the arm on the news here, albeit a more modest one this time around. European stocks are

Go to Forexlive